Sai Life Sciences Q3 Profit Surges 86%, Revenue Climbs 27% on Strong Growth

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Sai Life Sciences Q3 Profit Surges 86%, Revenue Climbs 27% on Strong Growth
Overview

Sai Life Sciences reported robust Q3 FY26 results, with Profit After Tax (PAT) soaring 86% year-on-year to ₹100 Cr. Revenue from operations grew by a strong 27% to ₹556 Cr, driven by excellent performance in CRO and CDMO services, improved operational efficiencies, and strategic investments in AI and digital platforms. EBITDA also saw a significant 54% jump to ₹191 Cr, with margins expanding substantially. The nine-month period also showcased impressive growth, with PAT up 199% and revenue up 43%.

📉 The Financial Deep Dive

Sai Life Sciences Limited has posted stellar financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26 and 9MFY26), underscoring significant operational and profit growth.

The Numbers:

  • Q3 FY26 Revenue: ₹556 Cr, a robust 27% increase year-on-year (YoY) from ₹440 Cr in Q3 FY25.

  • Q3 FY26 EBITDA: ₹191 Cr, up a substantial 54% YoY from ₹124 Cr in Q3 FY25.

  • Q3 FY26 EBITDA Margin: Expanded by 605 basis points to 34%, up from 28% in Q3 FY25.

  • Q3 FY26 PAT: Surged by 86% YoY to ₹100 Cr, compared to ₹54 Cr in Q3 FY25.

  • Q3 FY26 PAT Margin: Improved significantly to 18%, from 12% in the prior year period.

For the nine months ended December 2025 (9MFY26):
  • Revenue: ₹1,590 Cr, a strong 43% YoY increase from ₹1,115 Cr in 9MFY25.

  • EBITDA: ₹472 Cr, up 79% YoY from ₹264 Cr.

  • EBITDA Margin: Grew to 30% from 24% in 9MFY25.

  • PAT: Jumped by a remarkable 199% YoY to ₹245 Cr from ₹82 Cr.

  • PAT Margin: Expanded to 15% from 7% in 9MFY25.

The Quality & Drivers:
The company's performance is bolstered by strong demand across its Contract Research (CRO) and Contract Development and Manufacturing Organization (CDMO) services. Key growth catalysts identified include improved capacity utilization, enhanced operational efficiencies, and successful cost optimization initiatives. Strategic advancements in AI & Digital Platforms, such as applied AI for route design and ML-generated compounds, alongside the successful delivery of AI-designed macrocyclic peptides, highlight the company's commitment to innovation. Strengthening of Flow capabilities and implementation of automation further contribute to improved productivity and service delivery.

Financial Position & Outlook:
Capital expenditure as of date stood at ₹405 Cr against a planned ₹700 Cr for FY26, indicating prudent deployment of capital in line with long-term expansion and capability-building strategies. Management expressed confidence in sustaining this growth momentum, aiming to solidify Sai Life Sciences' position as a globally relevant science-led CRDMO. The CFO emphasized disciplined execution and prudent capital allocation, positioning the company for continued strong and profitable expansion. The company also highlighted its commitment to quality and sustainability, releasing its 6th Sustainability Report and achieving Green-level certification for laboratories.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.